[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Polycythaemia vera is an acquired myeloproliferative disorder characterised by a polycythaemia resulting of a clonal disorder arising in a multipotent hematopoietic stem cell. The increase of red cell mass exposes to a high risk of arterial or venous thrombosis and thus requires a cytoreductive treatment. An acquired genetic mutation in exon 12 of the JAK2 tyrosine kinase gene, leading to a substitution of a valine to a phenylalanine (V617F), has been described in most polycythaemia vera patients. This mutation increases the phosphorylation activity of JAK2, promotes the spontaneous cellular growth and induces erythrocytosis in a mouse model. Prevalence studies of V617F JAK2 mutation in different myeloproliferative disorders have found this genetic alteration in half of idiopathic myelofibrosis and in one third of essential thrombocythaemia. This finding is a huge progress in the understanding of polycythaemia vera physiopathology, it will be also an useful tool for the diagnosis of myeloproliferative disorders and it opens a new field for the development of targeted therapeutic approaches in these disorders.
Pargade
V
V
Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Paris. pascale.gaussem@egp.aphp.fr
Darnige
L
L
Gaussem
P
P
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D053614:Janus Kinase 2; D051379:Mice; D009154:Mutation; D010649:Phenylalanine; D011087:Polycythemia Vera / Q000235:genetics*; D017433:Protein Structure, Secondary; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D014633:Valine
D011518:Proto-Oncogene Proteins; D010649:Phenylalanine; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; C507926:Jak2 protein, mouse; D053614:Janus Kinase 2; D014633:Valine